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UM-EC-2 was established from a patient with poorly differ- 
entiated stage IB endometial carcinoma. This cell line produces 
tumors in nude mice that have the same histological features as 
the patient’s tumor. UM-EC-2 cells express &microglobulin, the 
epidermal growth factor receptor (EGF), and the H blood group 
antigen. This membrane antigen phenotype is consistent with cells 
of human endometrial origin. The karyotype of UM-EC-2 is fairly 
complex, with rearrangements affecting all chromosomes except 
3, 10, 14, 19, and 20. There were two populations of cells, a 
hyperdiploid population with a modal number of 53-55 and a 
hypertetraploid population with a modal number of 109. A pos- 
tulated sequence of events before and after tetraploidization is 
suggested based on the number of copies of individual chromo- 
somes and rearrangements. Comparison of the UM-EC-2 karyo- 
type to that of UM-EC-1 (a previously described line from a 
different patient with endometrial carcinoma) revealed that the 
two lines share eight very similar chromosome changes, which 
include loss of most of chromosome 4, breakpoints affecting prox- 
imal bands on 8p, loss of most of 9q, a breakpoint at 12q22, loss 
of 13q, breakpoints in proximal bands on 18q, and a breakpoint 
at 22~11. These changes may represent nonrandom chromosome 
abnormalities in poorly differentiated endometrial cancer. Estro- 
gen (ER) and progesterone (PgR) receptors were not detected in 
either the primary tumor or the cell line. Nevertheless, UM-EC- 
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2 cells were very sensitive to growth inhibition by tamoxifen 
(TAM) in vitro. One micromolar TAM caused 50% inhibition of 
cell growth, 2.5 pM caused cytostasis, and 5 pM TAM was 
cytotoxic, killing all cells after 5-7 days of exposure to the drug. 
Paradoxically, 100 nM estradiol (E,) caused a moderate increase 
in the growth of the cells but it did not prevent or reverse growth 
inhibitory effects of TAM. These findings support the concept 
that in some tumors TAM causes growth inhibition by an ER- 
independent mechanism. UM-EC-2 cells were also sensitive to 
growth regulation by EGF. Thus, these cells provide a new in 
vitro model of human endometrial cancer in which the roles of 
both TAM and EGF as growth regulatory substances can be 
investigated. 0 1990 Academic F’ress, Inc. 
INTRODUCTION 
The standard therapy for endometrial cancer is surgery 
but for residual disease after surgery or for the treatment 
of recurrent and advanced endometrial carcinoma, hor- 
monal therapy is usually employed. Objective responses 
have been achieved with progestins in 30-35% of patients 
[I ,2]; however, this treatment has not improved the 5- 
year survival of patients with advanced or recurrent dis- 
ease [3,4]. This response rate is not unexpected since 
many advanced tumors are poorly differentiated and fail 
to express steroid hormone receptors [5-71. Tamoxifen 
(TAM) has also been used in treatments of this group 
of patients but often after failure with progestin therapy; 
nevertheless, a response rate of 20% has been obtained 
[S-14]. In our laboratory we have been investigating the 
growth regulatory effects of TAM on endometrial car- 
cinomas in vitro. In experiments using four estrogen re- 
188 
00!&8258/!40 $1 SO 
Copyright 0 19!40 by Academic Press, Inc. 
AU rights of reproduction in any form reserved. 
UM-EC-2: TAMOXIFEN-SENSITIVE, ER-NEGATIVE ENDOMETRIAL CARCINOMA CELL LINE 189 
ceptor (ER)-negative, progesterone receptor (PgR)-neg- 
ative , progestin-resistant cell lines derived from 
moderately or poorly differentiated endometrial carci- 
nomas, we found that all four exhibited dose-dependent 
growth inhibition in response to TAM treatment [15]. 
We have now established and characterized a new ER- 
negative endometrial carcinoma cell line (UM-EC-2) 
from a patient with advanced poorly differentiated en- 
dometrial carcinoma and used this line to expand on our 
prior observations. In this report the characteristics of 
this line and the effects of TAM, estradiol (E,), and 
epidermal growth factor (EGF) on its in vitro growth are 
described. 
MATERIALS AND METHODS 
Clinical History 
The donor of the UM-EC-2 cell line was a 53-year-old 
gravida 3, para 3, white female with a prior medical 
history of lymphoma treated by radiation and chemo- 
therapy. Ten years after that treatment, she was referred 
to the University of Michigan Medical Center for treat- 
ment of stage IB, grade 3 endometrial carcinoma. At the 
time of surgery she was found to have an extensive 
endometrial carcinoma invading the full thickness of the 
cervix and myometrium, with tumor eroding through the 
anterior wall and the left comu of the uterus. Total ab- 
dominal hysterectomy, bilateral salpingo-oophorectomy, 
and partial cystectomy were performed. Postoperatively 
the patient was treated with medroxyprogesterone ace- 
tate (MPA) 160 mg/day. However, within 3 months, tu- 
mor progression was obvious, with metastatic spread to 
the lungs and bilateral ureteral obstruction. At this time 
treatment with doxorubicin was instituted. The patient 
failed to respond to this therapy and died of her disease 
soon after. 
Cell Culture and Serologic Reagents 
Tumor cells were cultured using standard techniques 
[16]. A portion of the tumor was transported to the lab- 
oratory where it was washed in triple-antibiotic solution 
consisting of Puck’s saline A containing penicillin (100 
U/ml), streptomycin (100 pg/ml), and amphotericin B 
(40 pg/ml). The tissue was then cut into small fragments 
and placed into plastic flasks. The fragments were al- 
lowed to adhere for several minutes and were then cov- 
ered with culture medium consisting of Dulbecco’s mod- 
ified Eagle’s medium supplemented with 1% (v/v) 
nonessential amino acids, 20 mM L-glutamine, 15% fetal 
bovine serum (FBS), penicillin (100 ccl), and strepto- 
mycin (100 &ml) (cDMEM). Fibroblasts were removed 
by brief treatments with trypsin and EDTA (315 U/ml 
trypsin activity and 0.2 M EDTA in Puck’s saline A) as 
needed [16]. When the tumor cells became confluent in 
the culture flasks, the cells were subcultured by detach- 
ment with trypsin and EDTA. Cultures of UM-EC-2 were 
tested by standard microbiological tests and were found 
to be free of mycoplasma contamination. Cultures at 
several early passages were frozen in liquid nitrogen. 
Cells were also grown for inoculation into athymic mice 
(Nu/Nu CDl) (Charles River). Logarithmically growing 
tumor cells in passage 7 were harvested from 75-cm’ 
flasks with trypsin-EDTA and 1 x 10’ to 5 x 10’ cells 
were inoculated under the skin on the flanks of two male 
and two female mice. Mice were examined at weekly 
intervals, and when the tumors reached a volume of 
approximately 0.5-l cm3 the mice were killed by cervical 
dislocation and the tumors were removed for histological 
examination. 
Antibody reagents used to characterize the cell surface 
antigens included rabbit antiserum to human &-micro- 
globulin and monoclonal antibodies to blood groups A 
and B (Accurate Chemical and Scientific Corp., West- 
bury, NY), human blood group typing antisera (Ortho 
Diagnostics, Raritan, NJ), and monoclonal antibodies 
UM-A9 and UM-GlO raised in our laboratory [ 17-201. 
Autoantibodies to the squamous cell-specific pemphigus 
and pemphigoid antigens were used as specificity con- 
trols 1161. EGFRl monoclonal antibody to the external 
domain of the EGF receptor [21] was purchased from 
Amersham, Skokie, Illinois. UM-EC-2 cells growing in 
monolayer cultures in %-well plates were tested for an- 
tigen expression using protein A and anti-immunoglob- 
ulin hemadsorption assays as described previously [22]. 
Cytogenetic Analysis 
UM-EC-2 cells in passage 1, passage 2, and passage 
4 were harvested and analyzed as described previously 
[22,23]. Eighteen cells in passage 1 and fifteen cells in 
passage 2 were fully analyzed. In addition, four passage 
4 cells and four passage 16 cells were karyotyped. C 
banding, RBG banding, and silver staining of the nu- 
cleolus organizing region (Ag-NOR) were performed as 
described earlier [22,23]. 
Estrogen and Progesterone Receptor Determination 
Fresh tumor or cultured cells were frozen in liquid 
nitrogen and were transported to the Ligand Laboratory 
where the ER and PgR content was determined using 
the dextran-charcoal method [24,25]. The cultured cells 
were grown for receptor assays as described previously 
[ 15,261. Tamoxifen citrate was generously provided by 
Leiras-Medica, Huhtamaki Oy, Turku, Finland. 17P-Es- 
tradiol was purchased from Sigma Chemical Company, 
St. Louis, Missouri, 
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Effects of Tamoxifen, Estradiol, and Epidermal Growth 
Factor on Cell Growth 
In each experiment testing the effects of TAM on UM- 
EC-2 cells, the MCF-7 breast cancer cell line [27] was 
used as a TAM-sensitive control. The effects of TAM 
on MCF-7 were consistent with those reported in earlier 
publications [15,26] and are not illustrated in this article. 
Cells in logarithmically growing cultures were harvested 
with trypsin-EDTA, washed, resuspended, counted, and 
distributed to the wells of 96-well plates (Costar Corp., 
Cambridge, MA). Cultures were fed daily with cDMEM 
containing 5% FBS stripped free of steroids by treatment 
with dextran-coated charcoal (DCC) (DS medium) [24]. 
After 3 days in culture the logarithmically growing cells 
were fed daily with D5 medium containing the appro- 
priate concentrations of TAM or estradiol (E2) prepared 
according to standard methods [15,26,28,29]. Control 
cultures were fed with D5 medium. To test the capacity 
of E2 to prevent growth inhibition by TAM, cultures were 
fed simultaneously with E, (100 IN) and TAM (3.5 PM). 
For this experiment the control cultures were fed with 
D5 medium containing either E, (100 nM) alone or TAM 
(3.5 CLM) alone. To determine whether UM-EC-2 cells 
recover from the growth inhibitory effect of TAM more 
rapidly in the presence of E2, cultures were treated with 
5 @I TAM for 3 days; then the medium was removed 
and cultures were fed daily either with D5 medium con- 
taining 100 n&f E2 or D5 medium alone and cell counts 
were performed every other day. Epidermal growth fac- 
tor was purchased from Collaborative Research, Inc., 
Cambridge, Massachusetts. To assess the effect of EGF 
on cell growth, EGF at a concentration of 1 nM was 
added to D5 medium and cultures were fed and harvested 
as described above. 
RESULTS 
Histology and in Vitro Culture 
The histology of the tumor from the patient was read 
as a poorly differentiated adenocarcinoma with extensive 
areas of necrosis. The neoplasm contained sheets of 
loosely organized malignant cells with focal areas of at- 
tempted gland formation. The histology of tumors formed 
in nude mice by UM-EC-2 cells were also read as poorly 
differentiated adenocarcinoma with focal areas of at- 
tempted gland formation. Both the original tumor and 
those formed in nude mice by cultured UM-EC-2 cells 
had a similar lacy stromal pattern and variable cyto- 
plasmic vacuolization that resulted in some areas with a 
clear cell appearance. In primary culture, UM-EC-2 cells 
grew slowly at first and were sufficiently confluent for 
passage only after 5 months in culture. The cells are 
small and grow in cell islands with a tendency to pile up 
in three-dimensional colonies. Examples of the histology 
of the patient’s tumor, a tumor formed in an athymic 
mouse after inoculation of cultured UM-EC-2 cells, and 
the appearance of UM-EC-2 are shown in Fig. 1. 
Cell Surface Antigen Expression 
The cell surface antigen expression of UM-EC-2 cells 
is shown in Fig. 2. Rabbit antiserum to human Pz-mi- 
croglobulin was used to detect class I histocompatibility 
antigen expression. This reagent binds strongly to UM- 
EC-2 cells (Fig. 2A). We previously observed in im- 
munoperoxidase assays on tissue sections that normal 
endometrial glands express blood group antigens con- 
sistent with the donor’s blood type (data not shown), 
The donor of the UM-EC-2 cell line is blood group 0. 
Accordingly, there was no binding of antibodies to blood 
group A or B (not shown). However, UM-EC-2 cells do 
strongly express the H type 2 blood group antigen cor- 
responding to blood type 0 as determined by binding of 
the H type 2-specific monoclonal antibody, UM-GlO [19] 
(Fig. 2B). UM-EC-2 cells do not express the A9 antigen 
defined by monoclonal antibody UM-A9 (Fig. 2C). This 
antigen is expressed by all squamous cell carcinomas 
and is found in the basal lamina of many glandular struc- 
tures including endometrial glands but is expressed only 
by a small proportion of adenocarcinomas [ 181. EGF 
receptor was strongly expressed on UM-EC-2 cells as 
determined by binding of the EGFRl monoclonal anti- 
body [21] (Fig. 2D). We found no reactivity of UM-EC- 
2 cells with antibodies to squamous cell-specific antigens 
[ 16,171 defined by autoantibodies from patients with pem- 
phigus vulgaris or bulbous pemphigoid (not shown). This 
phenotype is consistent with that expressed by the UM- 
EC-l endometrial carcinoma cell line [22]. 
Karyotype 
The UM-EC-2 cultures contained two cell populations. 
One population was hypertetraploid and the other was 
hyperdiploid. The proportion of the two populations dif- 
fered in lineages derived from separate primary flasks. 
Thus the population in the flask that was analyzed in 
passage 1 was predominantly hypertetraploid, with only 
two hyperdiploid cells. The cells in the flasks labeled 
passages 2, 4, and 16 were derived from a different pri- 
mary culture flask and these were predominantly hy- 
perdiploid (9/15 cells in culture P2, 7/7 in culture P4, 
and 3/4 in P16). Representative karyotypes are presented 
in Figs. 3 and 4. Rearrangements involving chromosomes 
1, 2, 4, 5, 6, 7, 8, 9, 11, 12, 13, 15, 16, 17, 18, 21, 22, 
and X were identified. Most of the rearrangements were 
common to both populations (Table 1 and Figs. 3 and 
4), but some additional changes occurred in each pop- 
ulation after the two populations became separate (Table 
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FIG. 1. Histology of the patient’s tumor, a tumor formed in a nude mouse inoculated with UM-EC-2 cells, and appearance of cultured 
cells at passage 4. (A) High-power photomicrograph of a section of the primary poorly differentiated endometrial carcinoma, showing pleo- 
morphism for cell size and shape, nested clusters of tumor cells, and areas of apparent lumen formation (arrows). (B) High-power photomicrograph 
of a section of a nude mouse tumor produced by passage 7 UM-EC-2 cells showing pleomorphism similar to that in the original tumor, nested 
clusters, and apparent lumen formation (arrows). (C) Inverted phase-contrast photomicrograph of passage 4 UM-EC-2 cells in culture Day 3 
after passage (240x). (D) Same culture as in C, shown on Day 8 after passage (80x). The cells grow in islands and have a tendency to pile 
up in three-dimensional colonies, mimicking the nested appearance observed in tissue sections, 
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FIG. 2. Cell surface antigen phenotype of UM-EC-2 cells. Antigen expression was determined using hemadsorption assays on cells growing 
in plastic 96-well plates. (A) Rabbit antiserum to human &microglobulin (oPZM). (B) Monoclonal antibody UM-A9 to an epithelial basement 
membrane antigen. (C) Monoclonal antibody UM-GlO to the H type 2 blood group precursor antigen [19]. (D) Commercial monoclonal antibody 
EGFRl to the external domain of the epidermal growth factor receptor [21]. 
2). A postulated sequence of events in the evolution of 
the karyotype was derived by analyzing the number of 
copies of each chromosome in the hyperdiploid and hy- 
pertetraploid populations as described previously [23]. 
In some cases the differences in C banding between the 
homologs could be used to distinguish which chromo- 
some was involved in the rearrangements. This postu- 
lated sequence is presented in Table 2. The rearrange- 
ments common to both populations are most readily 
appreciated from Figs. 3 and 4. These include del(2)(q), 
del(4)(q) (entire homolog lost in some cells of the hy- 
perdiploid population), der(6)t(6;12), del(7)(p), del(S)(p), 
der(9)t(9;9), dW)(q)7 i(dic( 11)) , der(12)t(12;21), 
deNl3Nh der(16)t(16;?), Wp), inv(i( 17q)), 
der(18)t(18;?), der(21)t(21;?), der(22)t(22;?), and 
der(X)t(X;15)(q22q15). In addition, there were from one 
to four inconsistent markers. 
Receptor Content and Effects of Tamoxifen and 
Estradiol on Cell Growth 
No ER or PgR were found either in the patient’s tumor 
or in UM-EC-2 cells grown in culture. In spite of the 
absence of receptors, the cells were very sensitive to 
TAM. The growth inhibitory effect of l-10 PM TAM 
on UM-EC-2 cells in logarithmic growth is illustrated in 
Fig. 5. After 4 days of daily feeding with 1 ph4 TAM, 
the growth of UM-EC-2 cells was retarded by 50% rel- 
ative to the control cultures fed with medium alone. 
There was cytostasis (i.e., no increase in cell number) 
in cultures treated with 2.5 PM TAM, and in cultures 
fed concentrations of 5-10 PM there was significant 
cytotoxicity. 
Estradiol (100 nM E2), when given alone, moderately 
stimulated the growth of UM-EC-2 cells (Fig. 6). How- 
ever, this concentration of Ez did not block the growth 
inhibition caused by 3.5 pM TAM when the two agents 
were added to the cultures simultaneously (Fig. 6). Sim- 
ilarly, when cultures were fed 5 pM TAM to induce 
growth inhibition and then tested for recovery of loga- 
rithmic growth there was no difference between cells 
recovering in D5 medium or in D5 medium supplemented 
with 100 nM E2 (Fig. 7). 
Effect of Epidermal Growth Factor on Cell Growth 
Moderately elevated expression of the EGF receptor 
was detected by binding of the EGFRl antibody (Fig. 
2). Korc et al. have reported that EGF inhibits growth 
of the RL95-2 endometrial carcinoma cell line [30]. 









FIG. 3. Karyotype of a metaphase from UM-EC-2, passage 1. There are three normal copies of chromosome 1 and two i(lq). There are 
two normal chromosomes 2 and two del(2)(q), and in this cell there was an additional chromosome 2 with unidentified material attached to 
distal 2q. This was not seen in any other metaphase. There are four normal chromosomes 3, two normal chromosomes 4, and two del(4)(q). 
There are two normal chromosomes 5 and two i(5p). There are three normal chromosomes 6 and two der(6). There are two normal chromosomes 
7, two del(7)(p), and one der(7). There is one normal chromosome 8, one del(S)(p), and one del(l)(q). There are two normal chromosomes 9, 
a der(9), and two del(9)(q). There are three normal chromosomes 10, four normal chromosomes 11, and two dic(l1). There are two normal 
chromosomes 12 and two der(l2). There are four normal chromosomes 13 and one del(l3)(q). The four chromosomes 14 and the two chromosomes 
15 are normal. There are three normal chromosomes 16, one der(l6)t(l6;?)(pl3.3;?), and one der(l6)t(ll;l6)(ql3;q24). There are two normal 
chromosomes 17, two i(l7p), and one inv(i(l7q)). There are three normal chromosomes 18 and one der(l8)t(lll;?)(q22;?). There are three normal 
chromosomes 19, four normal chromosomes 20, two normal chromosomes 21, and one der(21). There is one normal chromosome 22 and one 
der(22). There are two normal late-replicating (genetically inactivated) X chromosomes and two early replicating (genetically active) der(X). 
There were three marker chromosomes in this cell. The marker in the center is possibly a distorted inv(i(l7q)); most hypertetraploid cells had 
two copies of this chromosome. 
Therefore, it was of interest to examine the effect of 
EGF on the growth of UM-EC-2 cells. EGF (at a con- 
centration based on the experiments reported by Korc 
et al. [30]) was added to logarithmically growing cultures 
starting on Day 4 and cell growth was monitored for the 
next 11 days. As shown in Fig. 6, EGF had little effect 
on the growth of the cells at 3 days (Day 7), but thereafter 
a progressively greater difference in cell number between 
EGF-treated and control cultures was noted. By Day 15 
the growth of EGF-treated cultures was reduced to 73% 
of that in the control cultures. 
DISCUSSION 
UM-EC-2 is the second of three cell lines derived in 
our laboratory from patients with poorly differentiated 
endometrial adenocarcinoma. UM-EC-3 has not yet been 
fully characterized but some interesting comparisons can 
be made between the other two lines. The tumors from 
which UM-EC-1 and UM-EC-2 cell lines were estab- 
lished showed aggressive clinical behavior leading to 
metastatic spread in the donors. Characterization of 
these cell lines revealed both similarities and differences. 
Both lines produce tumors in nude mice that resemble 
the donors’ neoplasms. Furthermore, both lines strongly 
express class 1 histocompatibility antigens and the EGF 
receptor (expression of EGFR by UM-EC-1 is unpub- 
lished, Carey et al.). The expression of the EGF receptor 
was fairly high on UM-EC-2 when compared to normal 
fibroblasts and keratinocytes. The latter cell types show 
no reactivity with the EGFRl antibody at dilutions of 
l/100 or greater. However, the expression of this antigen 











FIG. 4. Karyotype of a metaphase from UM-EC-2, passage 2. There is one normal chromosome 1 and one der(1). The arrow points to the 
breakpoint on the der(1). There is one normal chromosome 2 and one deI(2)(q). The arrows point to the region on the normal two that is lost 
in the del(2)(q). Both chromosomes 3 appear normal. There is one normal chromosome 4. The del(4)(q) is not represented in this karyotype. 
There is one normal chromosome 5 and one i(5p). There are two normal chromosomes 6 and one der(6). The arrow shows the point on 6 
where the translocated material from 12q is attached. There is one normal chromosome 7 and one del(7)(p) with an arrow showing the region 
of the deleted material. There is one normal chromosome 8 (with an arrow pointing to the band that is lost from the deleted 8) and one del(8)(p). 
There is one normal chromosome 9, one der(9), and one del(9)(q). There are two normal chromosomes 11, one dic(ll), and one der(l1). There 
is one normal chromosome 12 and one der(l2), with an arrow pointing to the breakpoint between 12 and the translocated 21 material. There 
is one normal chromosome 13 (with arrows marking the region that is lost from the other chromosome) and one del(13). There are two normal 
chromosomes 14 and a single normal 15. There are two normal chromosomes 16 and one der(l6)t(ls;?)(p13;?) (arrow indicates the breakpoint 
for the translocated material). There is no normal chromosome 17 in this cell (most cells had one normal 17). There is a del(l7)(pl I), an i(17p), 
and an inv(i(l7q)). There is a normal chromosome 18, a der(l8)t(l8;?)(pll.l;?), and a der(lg)t(lg;?)(q22;?). There are two normal chromosomes 
19, three normal chromosomes 20, and one der(21), with an arrow marking the junction with the unidentified material. The normal chromosome 
21 is missing from this and some other cells. There is one normal chromosome 22. There is one normal X chromosome and one der(X) and 
from a t(X;15), with an arrow marking the junction between the two chromosome segments. There are four unidentified chromosomes in this 
metaphase (inconsistent markers). 
is relatively low on UM-EC-2 when compared to the 
EGFR-amplified breast cancer cell line MDA-MB-468, 
which has approximately lo6 receptors and a 50% end- 
point titer of l/12,800 with the EGFRI antibody (T. 
Carey et al., unpublished data). The two lines differ with 
respect to blood group antigen expression. UM-EC-l, 
which was derived from a blood group A individual, 
expresses neither the A nor the H precursor antigen, 
whereas UM-EC-2, which was derived from a blood 
group 0 individual, expresses the H antigen strongly. 
As expected, neither endometrial carcinoma cell line 
showed reactivity with antibodies to squamous cell 
antigens. 
Cytogenetic analyses performed previously with UM- 
EC-l [22] and in this study with UM-EC-2 suggest that 
endometrial carcinomas may have nonrandom chromo- 
some abnormalities. UM-EC-2 has a much more com- 
plicated karyotype than UM-EC-l. However, numerous 
similarities were present in each line. Both lines had loss 
of nearly all of chromosome 4, a derived chromosome 
8 with breakpoints in the short arm at band p23 in UM- 
EC-l and band p22 in UM-EC-2, a deletion of the long 
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TABLE 1 
Comparison of the Karyotypes of UM-EC-2, Passages 1, 2, and 4” 
Chromosome 
UM-EC-2-Pl 
CNb = 109 (hyperteraploid population) 
Consensus karyotype 
UM-EC-2-P2 UM-EC-2-P4 
CN = 55 (hyperdiploid) CN = 53 (hyperdiploid) 
Number of chromosome copies per cell relative 





















4 (some 3),+ two i(l)(pll) 
4 (some 3), + two de1(2)(q21q31) 
4 (some cells 3) 
4 (some 3), 
+ two del(4)(q23q33)(some 3) 
2, + two i(5p) 
4 (some 3),+ two die(6) 
t(6;12)(p24;ql4)(some 1) 
2, + two de1(7)(p22p15), 
+ der(7)t(7;?)(qll.2;?) 
2, + two de1(8)(p22p12)(some cells 1) 
+ de1(8)(q24.1q24.3) 
2, + two de1(9)(q13) 
+ der(9)t(9;9J(p2l;ql3) 
3 (some cells 4) 
4, + two die (ll)(q13) 
+ del(ll)(pl3) (some cells 0) 
2, + two der(l2)t(l2;2l)(q22;qll.2) 
4 (some cells 3) 
+ two de1(13)(q14q21) 
4 (some cells 1) 
2 
3 (some cells 2, some 1) 
+ two der(16)t(16;?)(p13.3;?) 
+ two der(l6)t(l1;16)(q13;q24) 
2, + two inv(i(l7q))t(q2l;q25) 
+ two i(17p) 
4 (some cells 3, some 2) 
+ two der(l8)t(l8;)(?q22;?) (some 1) 
4 (some cells 3, some 2) 
5 (some cells 4, some 3) 
2 or 3 (some cells 1) 
+ two der(21)t(21;?)(pl l;?) 
(some cells 1 some 0) 
2, + der(22)t(22;?)(pl l;?) 
(some cells 0) 
2-7 
2, + two der(X)t(X;15)(q22;q15) 
1, + der(l)t(l;?)(p36.3;?) Same 
2 (some l), +de1(2)(q2lq31) Same 
2 Same 
1, + de1(4)(q23q33)(some 0) 
1, + i(5p)(some 2, some 0) 
2, +dic(6)t(6;12)(p24;q14) 
1 
1, + Gp) 
Same 
1, +de1(7)(p22p15) 
1, + del(8hp22p12) 
1, + del(7)(p22p15) 





2, + die (ll)(q13) 


















3 (some cells 4, some 2) 
1 (some cells 0) 
+ der(21)t(21;?)(pl l;?) 
(some cells 0) 
1, + der(22)t(22;?)(pll;?) 
(some cells 0) 
l-2 









a Passages 1 and 2 were separate cultures; passage 4 came from passage 2. 
b Consensus number. 
arm of chromosome 9 with breakpoints at qll (UM-EC- 
1) and q13 (UM-EC-2), a common breakpoint at 12q22, 
loss of chromosome 13 (the entire homolog in UM-EC- 
1 and q14-q21 in UM-EC-2), and deletion or rearrange- 
ment of 18q with breakpoints in adjacent bands at q11.2 
and q21.3 in UM-EC-l and at q22 in UM-EC-2; both 
lines also had a translocation involving chromosome 
22~11. In fact, except for a difference in the breakpoints 
on chromosome 1 and the changes in chromosome 19, 
all of the chromosome abnormalities in UM-EC-l were 
also present in UM-EC-2. The common affected chro- 
mosome bands in these cell lines provide the starting 
points for the molecular genetic analysis of the genes 
that are routinely altered in poorly differentiated endo- 
metrial carcinoma. Furthermore, as other less advanced 
cancers are evaluated it will be possible to distinguish 
which of these changes are related to the highly malig- 
nant behavior exhibited by poorly differentiated tumors. 
In ER-positive cells 100 ti E2 is generally at the upper 
limit of the stimulatory range and higher concentrations 
usually inhibit cell growth. For example, growth stim- 
ulation of the ER-positive MCF-7 cell line occurs at E2 
TABLE 2 
Postulated Sequence of Cytogenetic Events in the Development of the Endometrial Carcinoma from Which the LJM-EC-2 Lines 
Were Established 
NOnnal Early changes in 




I (small C band) 




2 break at 9ql3+ 
(small C band) 
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del(BKp22pl2) del(SKp22p12) del(8p),del(Sp) 













(the I lql3-qter segment went to chromosome 16~1) 









































X (late replicating) 





































































(see chromosome II) 
13,13 13,13,13,13 13,13,13,13 
del(13) des(13);del(l3) two del(13) 
I4 l4,14 14,14 
14 14.14 14,14 
15 15,15 15,15 
16 
der(16)t(l6;?) 
one of 15 cells 
16.16 
two der(l6)t(16:?) 















inv(i(l7q)),inv(i(17q)) two inv(i(l7q)) 
18.18 IS,18 
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FIG. 5. Cell growth curves showing the effects of TAM on UM- 
ED-2 cells. Experiments were performed in medium containing 5% 
DCC-treated FBS. Daily feeding with medium containing TAM was 
begun on Day 3. Control (open circles), 1 pM TAM (solid circles), 
2.5 /AM TAM (solid triangles), 5 pM TAM (solid squares), 7.5 pM 
TAM (solid diamonds), and 10 pM TAM (open diamonds). 
concentrations ranging from 1 to 100 nM, whereas 
growth inhibition is observed at 1 p  E2 [28]. Steroid
hormone receptors could not be detected in UM-EC-2 
cells. However, 100 ti E2 stimulated the growth of these 
cells by an as yet unknown mechanism. At this time we 
cannot rule out that in these cells there may be an in- 
duction of ER in the presence of high concentrations of 
E2 that then mediates the growth stimulator-y effects we 
observed. 






DAY 4 DAY 7 DAY 9 DAY 13 DAY 15 
DAYS OF CULTURE 
FIG. 6. Effects of hormonal agents on the growth of Uhf-EC-2 
cells. Cells were plated and ahowed to resume logarithmic growth. 
Starting on Day 4 the cells were fed daily with either D5 medium 
(control = C) or with D5 medium containing 1 nM EGF (EGF), 100 
nM E, (E,), 3.5 pM TAM (T), or 3.5 PM TAM and 100 nM E2 (T + 
E,). Cell counts of three replicate cultures were performed on the days 
indicated. Results are expressed as cell number per 35-mm dish. 
106 
0 3 6 9 12 
Time in Days 
FIG. 7. Reversibility of the growth inhibitory effects of tamoxifen 
on UM-EC-2 cells. Cells in logarithmically growing cultures were har- 
vested and plated at 8 x 16 cells per well and fed for 3 days with 
D5 medium. Some wells were then fed with medium containing 5 pM 
TAM for 3 days to inhibit growth (solid squares). On Day 7 groups of 
wells were fed with D5 medium alone, with D5 medium containing 100 
nM E2, with D5 medium containing 5 PM TAM (T), or with D5 medium 
containing both 5 j&f TAM and 100 nM E, (T + E,). Cell counts 
were performed on three replicate cultures on the days indicated. 
cinemas often lack steroid receptors and exhibit a poor 
response to progestins [5-7,311. We recently demon- 
strated that TAM caused growth inhibition in four ER- 
and PgR-negative, MPA-resistant cell lines derived from 
moderately or poorly differentiated endometrial carci- 
nomas [15]. One of those cell lines, UM-EC-l [22], was 
established in our laboratory from a patient who had 
progression of her tumor during postoperative MPA ther- 
apy, but experienced an objective clinical response to 
subsequent TAM treatment [15]. Thus, there was a good 
correlation between our in vitro study and the clinical 
response in that patient. 
TAM also caused a dose-dependent growth inhibition 
of logarithmically growing UM-EC-2 cells in vitro. In 
fact UM-EC-2 is as sensitive to TAM as the MCF-7 
breast cancer cell line. MCF-7 is used in many labora- 
tories to study antihormone effects of TAM [32-341 and 
routinely exhibits cessation of logarithmic growth in 5 
198 GRENMAN ET AL. 
pM TAM [15,26,28,29]. Similar levels of growth inhi- 
bition were obtained in UM-EC-2 cultures with 2.5-3.5 
pM TAM. In UM-EC-2 cultures the growth inhibitory 
effect of TAM was not reversed by E2; likewise, cells 
removed from TAM did not recover more rapidly from 
growth inhibition in the presence of EZ. The inability of 
Ez to reverse the effects of TAM is consistent with ab- 
sence of measurable levels of the ER. These findings are 
also in agreement with our previous data obtained with 
other ER-negative cell lines including UM-EC-I 
[15,26,28,29] and support the concept of an ER-inde- 
pendent mechanism mediating part of the growth inhib- 
itory effects of TAM. Clinical studies show an overall 
response rate of 20% to TAM in patients with advanced 
or recurrent endometrial carcinoma [9-141. Steroid hor- 
mone receptor content of the tumors is unknown in most 
of the reports, and so it is not possible to draw any 
conclusions of the correlation of the response to TAM 
and the ER or PgR expression of the tumors. There is 
extensive literature showing evidence for distinct binding 
sites for nonsteroidal antiestrogens [35-371; however, the 
role of these antiestrogen binding sites in mediating the 
growth inhibition caused by TAM has not been dem- 
onstrated [36,37]. We have not yet determined whether 
there are specific antiestrogen binding sites in our ER- 
negative, TAM-sensitive cell lines. The mechanism by 
which TAM binds and regulates growth in ER-negative 
cells remains to be determined. The donor of UM-EC- 
2 died before we obtained the in vitro data showing how 
sensitive this tumor is to TAM. This is unfortunate be- 
cause the in vitro results and the beneficial effects of 
TAM in the donor of UM-EC-l suggest that TAM may 
have altered the course of her disease. 
EGF has growth stimulatory effects on normal cells, 
but in tumors where the receptor is overexpressed, EGF 
can be growth inhibitory. In fact, EGF has been reported 
to inhibit the proliferation of RL95-2 human endometrial 
carcinoma cells [30,38], and under similar conditions 
UM-EC-2 cells were also susceptible to growth inhibition 
by EGF in vitro. 
It has recently been shown that hormonal agents can 
modulate the levels of polypeptide growth factors and 
their receptors [30-431 and it has been suggested that 
growth factors may participate in postreceptor effects of 
estrogens and antiestrogens. Receptors for EGF are pres- 
ent in both normal [44,45] and malignant [30] human 
endometrial cells. It will be of interest to determine 
whether there is a link between the effects of steroid and 
polypeptide hormones on cell growth. UM-EC-2 cells 
provide a good model in which to study the interactions 
between growth factors, growth factor receptors, and 
growth regulatory antihormones such as TAM to better 
understand the mechanisms by which tumor growth may 
be controlled. 
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